Avenue Therapeutics, Inc. (ATXI)

Market price: $0.38

1 valuation method

• P / B: $0.64 to $1.18 (midpoint $0.91)

How each method works

P / B: $0.64 to $1.18 (midpoint $0.91)

Values the stock at a peer multiple of its book (net asset) value — most meaningful for asset-heavy and financial companies whose balance sheet drives value.

How it’s calculated

We take book value per share (total assets minus total liabilities, from the latest balance sheet, divided by shares outstanding) and multiply it by the range of price-to-book multiples the peer group trades at.

Why it fits this industry

Where the balance sheet is the business — lenders, insurers, asset-heavy operators — the price the market pays for a dollar of net assets is a natural yardstick.

Reading this bar

The bar is the per-share value range this method implies: a conservative low, a central estimate, and an optimistic high. If the current price sits below the bar, the market is pricing the shares below what this method's inputs suggest; if it sits above, the market is pricing them higher. No single bar is a verdict — methods disagree for good reasons, so read the whole field together. Asset-light companies (brands, software) legitimately trade far above book value, so for them a P/B bar well below the price is usually structure, not signal.

P / B = (3.69/5.26/6.84)× book_value_per_share 0.17 ≈ 0.64/0.91/1.18 (per_share)

6 methods not shown

• EV / EBITDA: ebitda unavailable — cannot form EV / EBITDA
• EV / Revenue: revenue is non-positive — EV/Revenue does not apply
• EV / Gross Profit: gross_profit unavailable — cannot form EV / Gross Profit
• P / E: diluted EPS is non-positive — P/E is not meaningful for a loss-making period
• DCF (FCFF): DCF input(s) unavailable (da, capex, delta_nwc, revenue_cagr) — cannot build FCFF
• P / E — adjusted: adjusted_eps unavailable — cannot form P / E — adjusted

Limited data — fewer than three valuation methods could be formed for this company; showing every method we can stand behind.